Malignant pleural effusions (MPE) are a commonly encountered clinical problem in patients with lung cancer, contributing to a poor quality of life in this group of patients. Chemical pleurodesis using various sclerosing agents is an accepted palliative therapy for patients with recurrent, symptomatic MPE.